Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 9Neoplasm Metastasis 2Colorectal Neoplasms 2Recurrence 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Gastric Cancer 1

Interventions

Paclitaxel 6apatinib 4camrelizumab 3S 1 (combination) 2Capecitabine 2130-nm albumin-bound paclitaxel 2vorolanib 1titanium silicide 1spartalizumab 1raltitrexed 1olaparib 1lobaplatin 1durvalumab 1Ramucirumab 1Oxaliplatin 1Gastrectomy 1Docetaxel 1Control Groups 1Cisplatin 1CF regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Gastric Cancer × titanium silicide × Clear all
NCT03137004 2017-05-08

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Unknown
47 enrolled
Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡